Abstract
The merger of GlaxoWellcome and SmithKlineBeecham in 2000 created the world’s second largest pharmaceutical company, GlaxoSmithKline. GSK also became the world’s leader in the provision of drugs to treat the three most critical diseases in the developing world: HIV/AIDS, malaria and tuberculosis. In addition to merger related strategy and restructuring activities, the company finds itself having to respond to pressures to increase access to these essential medicines in developing countries, including the possibility of major reductions in price. How should GSK respond to these pressures?
Keywords Applied Philosophy  Business and Professional Ethics  Teaching Philosophy
Categories (categorize this paper)
ISBN(s) 1649-5195
DOI jbee2005218
Options
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy


Upload a copy of this paper     Check publisher's policy     Papers currently archived: 72,577
External links

Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
Through your library

References found in this work BETA

No references found.

Add more references

Citations of this work BETA

No citations found.

Add more citations

Similar books and articles

GlaxoSmithKline and Access to Essential Medicines.N. Craig Smith & Anne Duncan - 2005 - Journal of Business Ethics Education 2 (1):123-132.
Patent Funded Access to Medicines.Tom Andreassen - 2015 - Developing World Bioethics 15 (3):152-161.
Corporate Responsibilities for Access to Medicines.Klaus M. Leisinger - 2009 - Journal of Business Ethics 85 (S1):3 - 23.

Analytics

Added to PP index
2012-03-18

Total views
59 ( #196,734 of 2,533,585 )

Recent downloads (6 months)
1 ( #390,861 of 2,533,585 )

How can I increase my downloads?

Downloads

My notes